Avid Bioservices Inc (CDMO)

[JJ1223]

Bayer : Patent Issued for Gla Domains as Targeting Agents (USPTO 9694048)

Bayer is scheduled to run a combo trial with Bavi through NCCN. Based on that, I assume they done a complete analysis on Bavituximab/PS. Today we see a Bayer patent filed the GLA domain protein that targets PS on the outside of the cell. This is an interesting development, and ties Peregrine, NCCN, and Bayer together
In the future development of PS Targeting.
My guess would be that PPHM is now an active take over target for Bayer. Make no mistake, this patent is a strong validation of PS in the future fight against disease. Whatever the result, we may hear something soon.